share_log

Viking Therapeutics | 8-K: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Viking Therapeutics | 8-K: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Viking Therapeutics | 8-K:Viking Therapeutics公佈2024年第二季度財務業績並提供公司最新情況
美股SEC公告 ·  2024/07/25 04:15

Moomoo AI 已提取核心訊息

Viking Therapeutics reported Q2 2024 financial results with a net loss of $22.3M and strong cash position of $942M. The company achieved significant progress across its pipeline programs, particularly in obesity and NASH treatments.Key clinical developments include plans to advance VK2735 into Phase 3 for obesity following successful Phase 2 VENTURE study results showing up to 14.7% weight reduction. The oral formulation of VK2735 demonstrated up to 5.3% weight loss in Phase 1, with Phase 2 trial planned for Q4 2024. The Phase 2b VOYAGE study of VK2809 for NASH met both primary and secondary endpoints, showing 63-75% NASH resolution rates.The company completed enrollment in the Phase 1b study of VK0214 for X-ALD with results expected in 2H 2024. Additionally, Viking presented promising preclinical data from its novel amylin agonist program at ADA, with IND filing planned for 2025. R&D expenses increased to $23.8M from $13.9M YoY, reflecting expanded clinical development activities.
Viking Therapeutics reported Q2 2024 financial results with a net loss of $22.3M and strong cash position of $942M. The company achieved significant progress across its pipeline programs, particularly in obesity and NASH treatments.Key clinical developments include plans to advance VK2735 into Phase 3 for obesity following successful Phase 2 VENTURE study results showing up to 14.7% weight reduction. The oral formulation of VK2735 demonstrated up to 5.3% weight loss in Phase 1, with Phase 2 trial planned for Q4 2024. The Phase 2b VOYAGE study of VK2809 for NASH met both primary and secondary endpoints, showing 63-75% NASH resolution rates.The company completed enrollment in the Phase 1b study of VK0214 for X-ALD with results expected in 2H 2024. Additionally, Viking presented promising preclinical data from its novel amylin agonist program at ADA, with IND filing planned for 2025. R&D expenses increased to $23.8M from $13.9M YoY, reflecting expanded clinical development activities.
Viking Therapeutics發佈了2024年第二季度財務報告,淨虧損爲2230萬美元,現金狀況良好,達到94200萬美元。公司在其管線項目中取得了顯著進展,特別是在肥胖症和NASH治療方面。關鍵臨牀進展包括計劃將VK2735推進至肥胖症的第三階段,繼成功的第二階段創業公司研究結果顯示體重減少高達14.7%之後。VK2735的口服配方在第一階段顯示出高達5.3%的體重減輕,預計第二階段試驗將在2024年第四季度進行。VK2809在NASH的20億階段VOYAGE研究滿足了所有主要和次要終點,顯示NASH改善率爲63-75%。公司已完成對VK0214在X-ALD的10億階段研究的入組,預計結果將在2024年下半年公佈。此外,Viking在ADA上展示了其新型澱粉酶激動劑項目的有希望的臨牀前數據,計劃於2025年提交IND申請。研發費用同比增加至2380萬美元,從1390萬美元反映出臨牀開發活動的擴大。
Viking Therapeutics發佈了2024年第二季度財務報告,淨虧損爲2230萬美元,現金狀況良好,達到94200萬美元。公司在其管線項目中取得了顯著進展,特別是在肥胖症和NASH治療方面。關鍵臨牀進展包括計劃將VK2735推進至肥胖症的第三階段,繼成功的第二階段創業公司研究結果顯示體重減少高達14.7%之後。VK2735的口服配方在第一階段顯示出高達5.3%的體重減輕,預計第二階段試驗將在2024年第四季度進行。VK2809在NASH的20億階段VOYAGE研究滿足了所有主要和次要終點,顯示NASH改善率爲63-75%。公司已完成對VK0214在X-ALD的10億階段研究的入組,預計結果將在2024年下半年公佈。此外,Viking在ADA上展示了其新型澱粉酶激動劑項目的有希望的臨牀前數據,計劃於2025年提交IND申請。研發費用同比增加至2380萬美元,從1390萬美元反映出臨牀開發活動的擴大。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息